- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cognition Therapeutics Inc (CGTX)
Cognition Therapeutics Inc stock price live, this page displays NASDAQ CGTX stock exchange data. View the CGTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cognition Therapeutics Inc real time stock price chart below.
What Is the Cognition Therapeutics Inc Stock Price Today?
The Cognition Therapeutics Inc stock price today is 1.550.
What Is the Stock Symbol for Cognition Therapeutics Inc?
The stock symbol for Cognition Therapeutics Inc is ""CGTX.""
What Stock Exchange Does Cognition Therapeutics Inc Trade On?
Cognition Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cognition Therapeutics Inc a Good Stock to Buy?
Determining whether Cognition Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGTX quote. (ISIN: US19243B1026)
What Is the Cognition Therapeutics Inc Stock Price Today?
The Cognition Therapeutics Inc stock price today is 1.550.
What Is the Stock Symbol for Cognition Therapeutics Inc?
The stock symbol for Cognition Therapeutics Inc is ""CGTX.""
What Stock Exchange Does Cognition Therapeutics Inc Trade On?
Cognition Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cognition Therapeutics Inc a Good Stock to Buy?
Determining whether Cognition Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGTX quote. (ISIN: US19243B1026)
NASDAQ
Currency in USD
Fair Value
An estimate of a Cognition Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.402
1.590
52 wk Range
0.222
3.830
Unusual Post-Market activity
1/2
Fair Value
An estimate of a Cognition Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4021.590
52 wk Range
0.2223.830
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CGTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Cognition Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
3.250
Upside
+109.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K Cognition Therapeutics Inc For: 6 November
- Investing.com
- Form 8K Cognition Therapeutics Inc For: 6 November
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Cognition Therapeutics Inc Company Profile
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Cognition Therapeutics Inc Earnings Call Summary for Q4/2024
- Net loss of $34M for 2024, unchanged from 2023 at $0.86 per share; stock stable at $0.45 in premarket trading
- Strategic focus on Alzheimer's and DLB programs; discontinuing other projects to optimize resource allocation
- $12.8M raised through ATM facility, extending cash runway into Q4 2025; $25M cash on hand as of Dec 31, 2024
- Preparing for potential Phase III trials in Alzheimer's and DLB; exploring lower dose levels in future studies
- Confident in regaining NASDAQ compliance by September 2025; seeking non-dilutive funding through partnerships
Last Updated: 20/03/2025, 13:52
Read Full TranscriptCompare CGTX to Peers and Sector
Metrics to compare | CGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCGTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.9x | −2.5x | −0.6x | |
PEG Ratio | −0.09 | −0.04 | 0.00 | |
Price/Book | 3.7x | 1.5x | 2.6x | |
Price / LTM Sales | - | 8.1x | 3.3x | |
Upside (Analyst Target) | 125.8% | 256.6% | 41.5% | |
Fair Value Upside | Unlock | 4.5% | 5.1% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.250
(+109.68% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.06 / -0.10
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Cognition Therapeutics (CGTX) Premarket Price Today?
The Cognition Therapeutics (CGTX) premarket price is 1.450. Premarket price change units: -0.090. Premarket percentage change: -5.840%. Premarket volume: 114,040.000. Current date: 17 Nov 2025. Previous close: 1.540
What Stock Exchange Does Cognition Therapeutics Trade On?
Cognition Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Cognition Therapeutics?
The stock symbol for Cognition Therapeutics is "CGTX."
What Is the Cognition Therapeutics (CGTX) Afterhours Price Today? (Afterhours variable test: 1.630) Current Date: 17 Nov 2025
After hours price: 1.630. After hours price change (units): 0.080. Price change percentage: 5.160%
What Is the Cognition Therapeutics Market Cap?
As of today, Cognition Therapeutics market cap is 136.83M.
What Is Cognition Therapeutics's Earnings Per Share (TTM)?
The Cognition Therapeutics EPS (TTM) is -0.46.
When Is the Next Cognition Therapeutics Earnings Date?
Cognition Therapeutics will release its next earnings report on 31 Mar 2026.
From a Technical Analysis Perspective, Is CGTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cognition Therapeutics Stock Split?
Cognition Therapeutics has split 0 times.
How Many Employees Does Cognition Therapeutics Have?
Cognition Therapeutics has 27 employees.
What is the current trading status of Cognition Therapeutics (CGTX)?
As of 17 Nov 2025, Cognition Therapeutics (CGTX) is trading at a price of 1.550, with a previous close of 1.540. The stock has fluctuated within a day range of 1.402 to 1.590, while its 52-week range spans from 0.222 to 3.830.
What Is Cognition Therapeutics (CGTX) Price Target According to Analysts?
The average 12-month price target for Cognition Therapeutics is USD3.25, with a high estimate of USD4 and a low estimate of USD2. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +109.68% Upside potential.
What Is the CGTX Premarket Price?
CGTX's last pre-market stock price is 1.450. The pre-market share volume is 114,040.000, and the stock has decreased by -0.090, or -5.840%.
What Is the CGTX After Hours Price?
CGTX's last after hours stock price is 1.630, the stock has decreased by 0.080, or 5.160%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.